A Study of ABT-378/Ritonavir Combination in HIV-Infected Patients Who Have Taken Protease Inhibitors
- Conditions
- HIV Infections
- Registration Number
- NCT00004580
- Lead Sponsor
- Abbott
- Brief Summary
The purpose of this study is to see if it is safe and effective to give ABT-378/ritonavir combination plus nevirapine plus two nucleoside transcriptase inhibitors to HIV-infected patients who previously have taken protease inhibitors. This study also examines how the body handles this combination of anti-HIV drugs.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (10)
Univ of Cincinnati Med Ctr / Holmes Div Mail Loc 0405
🇺🇸Cincinnati, Ohio, United States
Pacific Oaks Research
🇺🇸Beverly Hills, California, United States
Duke Univ Med Ctr / Infectious Disease Clinic
🇺🇸Durham, North Carolina, United States
AIDS Research Consortium of Atlanta
🇺🇸Atlanta, Georgia, United States
San Francisco Gen Hosp / UCSF AIDS Program
🇺🇸San Francisco, California, United States
Infectious Disease Physicians Inc
🇺🇸Annandale, Virginia, United States
Univ North Carolina at Chapel Hill / Dept of Medicine
🇺🇸Chapel Hill, North Carolina, United States
Univ of Colorado Health Sciences Ctr
🇺🇸Denver, Colorado, United States
Univ of Pittsburgh
🇺🇸Pittsburgh, Pennsylvania, United States
Rush Presbyterian St Lukes Med Ctr / Sect Infect Dise
🇺🇸Chicago, Illinois, United States